Metastatic Castration Resistant Prostate Cancer (mCRPC)
Conditions
Brief summary
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
DRUGRadium-223 dichloride (Xofigo, BAY88-8223)
Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients with documented diagnosis of mCRPC (≥18 years at diagnosis), and * Received Ra-223 as one of the therapies between Jan 1, 2013 and Jun 31, 2019 after diagnosis of mCRPC
Exclusion criteria
\- Patients involved in clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival from initiation of Ra-223 | Retrospective analysis from Jan 2013 to Dec 2019 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Prostate Specific Antigen (PSA) (unit: µg/L) response after Ra-223 | Retrospective analysis from Jan 2013 to Dec 2019 | PSA response will be defined ≥ 50% reduction in baseline PSA level after initiation of Ra-223 |
Countries
United States
Outcome results
None listed